Ruqayya Afridi

Dr. Ruqayya Afridi

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in International Immunopharmacology
Verified
Journal Article
Closed access
MUMuhammad Zia Ullah
Muhammad Zia Ullah
AKAshraf Ullah Khan
Ashraf Ullah Khan
RARuqayya Afridi
Ruqayya Afridi
HRHina Rasheed
Hina Rasheed
SKSidra Khalid
Sidra Khalid
SKSalman Khan
Salman Khan

31 May 2023 in Cells
Verified
Journal Article
Open access
PDF file
RARuqayya Afridi
Ruqayya Afridi
Kyoungho SukKyoungho Suk
Kyoungho Suk
Chronic stress is a major risk factor for various psychiatric diseases, including depression; it triggers various cellular and structural changes, resulting in the alteration of neurocircuitry and subsequent development of depression. Accumulating evidence suggests that microglial cells orchestrate stress-induced depression. Preclinical studies of stress-induced depression revealed microglial inflammatory activation in regions of the brain that regulate mood. Although studies have identified several molecules that trigger inflammatory responses in microglia, the pathways that regulate stress-induced microglial activation remain unclear. Understanding the exact triggers that induce microglial inflammatory activation can help find therapeutic targets in order to treat depression. In the current review, we summarize the recent literature on possible sources of microglial inflammatory activation in animal models of chronic stress-induced depression. In addition, we describe how microglial inflammatory signaling affects neuronal health and causes depressive-like behavior in animal models. Finally, we propose ways to target the microglial inflammatory cascade to treat depressive disorders.

8 October 2022 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
JKJong-Heon Kim
Jong-Heon Kim
RARuqayya Afridi
Ruqayya Afridi
ECEunji Cho
Eunji Cho
JYJong Hyuk Yoon
Jong Hyuk Yoon
YLYong-Hyun Lim
Yong-Hyun Lim
Kyoungho SukKyoungho Suk
Kyoungho Suk
Astrocytes are major supportive glia and immune modulators in the brain; they are highly secretory in nature and interact with other cell types via their secreted proteomes. To understand how astrocytes communicate during neuroinflammation, we profiled the secretome of human astrocytes following stimulation with proinflammatory factors. A total of 149 proteins were significantly upregulated in stimulated astrocytes, and a bioinformatics analysis of the astrocyte secretome revealed that the brain renin–angiotensin system (RAS) is an important mechanism of astrocyte communication. We observed that the levels of soluble form of aminopeptidase N (sANPEP), an RAS component that converts angiotensin (Ang) III to Ang IV in a neuroinflammatory milieu, significantly increased in the astrocyte secretome. To elucidate the role of sANPEP and Ang IV in neuroinflammation, we first evaluated the expression of Ang IV receptors in human glial cells because Ang IV mediates biological effects through its receptors. The expression of angiotensin type 1 receptor was considerably upregulated in activated human microglial cells but not in human astrocytes. Moreover, interleukin-1β release from human microglial cells was synergistically increased by cotreatment with sANPEP and its substrate, Ang III, suggesting the proinflammatory action of Ang IV generated by sANPEP. In a mouse neuroinflammation model, brain microglial activation and proinflammatory cytokine expression levels were increased by intracerebroventricular injection of sANPEP and attenuated by an enzymatic inhibitor and neutralizing antibody against sANPEP. Collectively, our results indicate that astrocytic sANPEP–induced increase in Ang IV exacerbates neuroinflammation by interacting with microglial proinflammatory receptor angiotensin type 1 receptor, highlighting an important role of indirect crosstalk between astrocytes and microglia through the brain RAS in neuroinflammation.

14 February 2022 in Cells
Verified
Journal Article
Open access
PDF file
RARuqayya Afridi
Ruqayya Afridi
MTMakoto Tsuda
Makoto Tsuda
HRHoon Ryu
Hoon Ryu
Kyoungho SukKyoungho Suk
Kyoungho Suk
The historical concept of glia just as the glue of brain tissue has been challenged by the accumulation of concrete evidence showing the multifunctional role of these cells during development and in the adult brain

28 April 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
RARuqayya Afridi
Ruqayya Afridi
Kyoungho SukKyoungho Suk
Kyoungho Suk
Chronic stress is a major risk factor for various psychiatric diseases, including depression; it induces a range of cellular and structural adaptations, culminating in altered neurocircuitry and subsequent depression. Accumulating evidence suggests that microglial cells orchestrate stress-induced depression. Preclinical studies of stress-induced depression revealed microglial inflammatory activation in regions of the brain that regulate mood. Although studies have identified several molecules that trigger inflammatory responses in microglia, the pathways that regulate stress-induced microglial activation remain unclear. Understanding the exact triggers that induce microglial inflammatory activation can help find therapeutic targets to treat depression. In the current review, we summarize the recent literature on possible sources of microglial inflammatory activation in animal models of chronic stress-induced depression. In addition, we describe how microglial inflammatory signaling affects neuronal health and causes depressive behavior. Finally, we propose ways to target the microglial inflammatory cascade to treat depressive disorders.

30 December 2021 in Main Group Chemistry
Verified
Journal Article
Closed access
PDF file
MAMaryam Afridi
Maryam Afridi
SKSaeed Ahmad Khan
Saeed Ahmad Khan
RARuqayya Afridi
Ruqayya Afridi
FUFarman Ullah
Farman Ullah
AMAbdul Majid
Abdul Majid
NANawab Ali
Nawab Ali
Growing resistance to currently approved antibiotics is posing serious concern worldwide. The multidrug-resistant organisms are a major cause of mortality and morbidity around the globe. The limited options to treat infections caused by resistant organism requires alternative strategies to increase the effectiveness of antibiotic for better clinical outcomes. Recent advances in nanotechnology have enabled the drugs to be used in nanoscale to increase the effectiveness of antibiotics. The use of nanoparticles to treat infectious diseases has a long history in the pharmaceutical market, and the versatility of these particles to incorporate various materials as carriers make it an attractive option to combat the current crisis of emerging antibacterial resistance. Silver, a metal with many medical applications, has inherent antimicrobial properties. Therefore, silver NPs are appearing as one of the best options to be used in combination with antibiotics to increase effectiveness against resistant bacteria. Here, we discuss the applications and mechanisms of silver NPs to treat microbial resistance in light of recent research.